Antigenically dominant proteins within the human liver mitochondrial proteome identified by monoclonal antibodies

Science China Life Sciences

Volumn 54, Issue 1, 2011, Pages 16-24

  Ju, Yan Fang ^a   Yang, Jin Ju ^b   Liu, Rong ^b   Liu, Xiao Lan ^b   Du, Xue Mei ^b   Liu, Li ^b   Chen, Zhi Cheng ^b   Chi, Jun ^b   Liu, Shu Er ^b   Gao, Yuan ^b   Gao, Jian En ^b   Jiao, Shun Chang ^a   He, Fu Chu ^b   Sun, Qi Hong ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

antigenically dominant proteins; cDNA library screening; liver; mitochondria; monoclonal antibodies

Indexed keywords

EID: 78751668733     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-4115-0     Document Type: Article

References (51)

1. Darley-Usmar V M, Rickwood D, Wilson M T. Mitochondria: a Practical Approach. Oxford: IRL Press, 1987.
2. Cordwell S J, Wilkins M R, Cerpa-Poljak A, et al. Cross-species identification of proteins separated by two-dimensional gel electrophoresis using matrix-assisted laser desorption ionisation/time-of-flight mass spectrometry and amino acid composition. Electrophoresis, 1995, 16: 438-443.
3. Taylor S W, Fahy D, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol, 2003, 21: 281-286.
4. Kusnezow W, Hoheisel J D. Antibody microarrays: promises and problems. Biotechniques, 2002, Suppl: 14-23.
5. Lemasters J J, Qian T, Bradham C A, et al. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J Bio energ Biomembr, 1999, 31: 305-319.
6. Beal M F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci, 2000, 23: 298-304.
7. Chinnery P F, Howell N, Andrews R M, et al. Mitochondrial DNA analysis: polymorphisms and pathogenicity. J Med Genet, 1999, 36: 505-510.
8. Parrella P, Xiao Y, Fliss M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res, 2001, 61: 7623-7626.
9. Hibi K, Nakayama H, Yamazaki T, et al. Mitochondrial DNA alteration in esophageal cancer. Int J Cancer, 2001, 92: 319-321.
10. Simonnet H, Alazard N, Pfeiffer K, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis, 2002, 23: 759-768.
11. Copeland W C, Wachsman J T, Johnson F M, et al. Mitochondrial DNA alterations in cancer. Cancer Invest, 2002, 20: 557-569.
12. Modica-Napolitano J S, Singh K K. Mitochondrial dysfunction in cancer. Mitochondron, 2004, 4: 755-762.
13. Leonard J V, Schapira A H. Mitochondrial respiratory chain disorders II: eurodegenerative disorders and nuclear gene defects. Lancet, 2000, 355: 389-394.
14. Leonard J V, Schapira A H. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet, 2000, 355: 299-304.
15. DiMauro S, Bonilla E, Davidson M, et al. Mitochondria in neuromuscular disorders. Biochim Biophys Acta, 1998, 1366: 199-210.
16. Zeviani M, Spinazzola A, Carelli V. Nuclear genes in mitochondrial disorders. Curr Opin Genet Dev, 2003, 13: 262-270.
17. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun, 1989, 163: 1450-1455.
18. Schapira A H, Cooper J M, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990, 54: 823-827.
19. Betarbet R, Sherer T B, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 2000, 3: 1301-1306.
20. Kim S H, Vlkolinsky R, Cairns N, et al. The reduction of NADH: Ubiquinone oxidoreductase 24- and 75-kD subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci, 2001, 68: 2741-2750.
21. Arenas J, Campos Y, Ribacoba R, et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol, 1998, 43: 397-400.
22. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain, 2000, 123: 1339-1348.
23. Vielhaber S, Schroder R, Winkler K, et al. Defective mitochondrial oxidative phosphorylation in myopathies with tubular aggregates originating from sarcoplasmic reticulum. J Neuropathol Exp Neurol, 2001, 60: 1032-1040.
24. Dror N, Klein E, Karry R, et al. State-dependent alterations in mitochondrial complex I activity in platelets: A potential peripheral marker for schizophrenia. Mol Psychiatry, 2002, 7: 995-1001.
25. Lenaz G, D'Aurelio M, Merlo Pich M, et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta, 2000, 1459: 397-404.
26. Ling Y H, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol, 2008, 74: 793-806.
27. Murray J, Zhang B, Taylor S W, et al. The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification. J Bio Chem, 2003, 278: 13619-13622.
28. Sercarz E E, Lehmann P V, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol, 1993, 11: 729-766.
29. Wienhold W, Malcherek G, Jung C, et al. An example of immunodominance: engagement of synonymous TCR by invariant CDR3β. Int Immunol, 2000, 12: 747-756.
30. Gao J, Gao Y, Ju Y, et al. Proteomics-based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins. Proteomics, 2006, 6: 427-437.
31. Mootha V K, Bunkenborg J, Olsen J V, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell, 2003, 115: 629-640.
32. Lusty C J. Carbamoylphosphate synthetase I of rat liver mitochondria: Purification, properties, and polypeptide molecular weight. Eur J Biochem, 1978, 85: 373-383.
33. Raymond Y, Shore G C. Biogenesis of the mitochondrial enzyme, carbamyl phosphate synthetase: Appearance during fetal development of rat liver and rapid repression in freshly dispersed hepatocytes. Biochim Biophys Acta, 1981, 656: 111-119.
34. Saarelainen S, Zeiler T, Rautiainen J, et al. Lipocalin allergen Bos d 2 is a weak immunogen. Int Immunol, 2002, 14: 401-409.
35. Nagata N, Matsuda I, Qyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet, 1991, 39: 228-229.
36. Cardona D M, Zhang X, Liu C. Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. Am J Clin Pathol, 2009, 132: 877-882.
37. Head R A, Brown R M, Zolkipli Z, et al. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: Dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol, 2005, 58: 234-241.
38. Haselbeck R J, Hoffmann I, Duester G. Distinct functions for Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid signaling pathways. Dev Genet, 1999, 25: 353-364.
39. Molotkov A, Duester G. Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. J Biol Chem, 2003, 278: 36085-36090.
40. Moreb J S, Baker H V, Chang L J, et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer, 2008, 7: 87.
41. Levi B P, Yilmaz O H, Duester G, et al. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood, 2009, 113: 1670-1680.
42. Moreb J S, Mohuczy D, Ostmark B, et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmaco, 2007, 59: 127-136.
43. Ekhart C, Rodenhuis S, Smits P H, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genom, 2008, 18: 1009-1015.
44. Jackson S, Kler R S, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest, 1992, 90: 1219-1225.
45. Cao W, Liu N, Tang S, et al. Acetyl-Coenzyme A acyltransferase 2 attenuates the apoptotic effects of BNIP3 in two human cell lines. Biochim Biophys Acta, 2008, 1780: 873-880.
46. Vallat L, Magdelénat H, Merle-Béral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood, 2003, 101: 4598-4606.
47. Stegk J P, Ebert B, Martin H J, et al. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol, 2009, 301: 104-108.
48. Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem, 2008, 8: 702-710.
49. Hwang J Y, Lee S H, Kim G S, et al. HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone, 2009, 45: 1098-1103.
50. Tashjian R Z, Lin C, Aswad B, et al. 11beta-hydroxysteroid dehydrogenase type 1 expression in periprosthetic osteolysis. Orthopedics, 2008, 31: 545.
51. Ahmed A, Saksena S, Sherlock M, et al. Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf), 2008, 68: 898-903.